Palm Treo

Treos Bio Announces Presentation of Final Results from Phase 1b Study of PolyPEPI1018 Immunotherapy for Late-Stage Metastatic Colorectal Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Monday, June 5, 2023

PolyPEPI1018 is an off-the-shelf, multi-peptide vaccine derived from seven tumor associated antigens frequently expressed in patients with mCRC.

Key Points: 
  • PolyPEPI1018 is an off-the-shelf, multi-peptide vaccine derived from seven tumor associated antigens frequently expressed in patients with mCRC.
  • Final results from the study, conducted by Mayo Clinic in Minnesota, demonstrate that PolyPEPI1018 in combination with TAS-102 improved progression free-survival (PFS) and overall survival (OS) compared to historical data for standard of care TAS-102 alone.
  • “Importantly, these results show consistency between immunological responses and efficacy, and a particularly enhanced benefit in patients without liver metastasis.
  • Final results from the study demonstrate that PolyPEPI1018 and TAS-102 were safe and tolerable in combination with safety and toxicity profiles similar to TAS-102 monotherapy.

Treos Bio Announces First Patient Dosed in Phase 2 Trial of PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor for the Treatment of Metastatic Colorectal Cancer

Retrieved on: 
Monday, June 27, 2022

OBERTO 301 is a multicenter, open label, Phase 2 trial evaluating the combination treatment of PolyPEPI1018 and atezolizumab in patients with metastatic colorectal cancer (MSS mCRC) who have progressed on two or three prior treatment regimens.

Key Points: 
  • OBERTO 301 is a multicenter, open label, Phase 2 trial evaluating the combination treatment of PolyPEPI1018 and atezolizumab in patients with metastatic colorectal cancer (MSS mCRC) who have progressed on two or three prior treatment regimens.
  • PolyPEPI1018, Treos lead product candidate, is an immunotherapy in clinical development for the treatment of metastatic colorectal cancer, with plans to incorporate a candidate companion diagnostic in future clinical trials.
  • Treos Bio develops precision peptide cancer immunotherapies using proprietary computational data science integrating HLA genetics, tumor profile and clinical outcome of thousands of real subjects.
  • Treos lead candidate is PolyPEPI1018, an off-the-shelf immunotherapy for the treatment of metastatic colorectal cancer currently in a Phase 1b clinical trial which also investigates proprietary and novel biomarkers.

Treos Bio Announces First Patient Dosed in Phase 1b Trial of PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer

Retrieved on: 
Monday, February 7, 2022

PolyPEPI1018 previously demonstrated robust immune responses and initial efficacy in maintenance-stage therapy for mCRC in our completed Phase 1/2 trial.

Key Points: 
  • PolyPEPI1018 previously demonstrated robust immune responses and initial efficacy in maintenance-stage therapy for mCRC in our completed Phase 1/2 trial.
  • OBERTO 201 is a single arm, open-label, investigator-initiated Phase 1b trial evaluating 15 patients with metastatic colorectal cancer who are beginning a third-line treatment of the oral chemotherapy TAS-102.
  • PolyPEPI1018, Treos lead product candidate, is an immunotherapy in clinical development for the treatment of metastatic colorectal cancer, with plans to incorporate a candidate companion diagnostic in future clinical trials.
  • Treos lead candidate is PolyPEPI1018, an off-the-shelf immunotherapy for the treatment of metastatic colorectal cancer currently in a Phase 1b clinical trial which also investigates proprietary and novel biomarkers.

Treos Bio Announces the Appointment of Ruti Alon to its Board of Directors

Retrieved on: 
Tuesday, June 1, 2021

LONDON, June 01, 2021 (GLOBE NEWSWIRE) -- Treos Bio Limited (Treos), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies, today announced the appointment of Ruti Alon to its Board of Directors.

Key Points: 
  • LONDON, June 01, 2021 (GLOBE NEWSWIRE) -- Treos Bio Limited (Treos), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies, today announced the appointment of Ruti Alon to its Board of Directors.
  • Ms. Alon joins Treos with over 40 years of executive and entrepreneurial expertise as a life sciences investor, mentor and leader for private and public biotechnology companies.
  • I am excited to join Treos Bio, a company dedicated to transforming the cancer immunotherapy treatment paradigm, commented Ms. Alon.
  • Treos Bio uses computational data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide-based cancer immunotherapies.